Amgen Inc

Stock Symbol: AMGN

Amgen Inc Description:
Amgen, Inc. is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. The Company manufactures and markets four human therapeutic products, EPOGEN (Epoetin alfa), NEUPOGEN (Filgrastim), INFERGEN (Interferon alfacon-1) and STEMGEN (Ancestim). Amgen uses wholesale distributors of pharmaceutical products as the principal means of distributing the Company's products to clinics, hospitals and pharmacies.

Amgen Inc Financial Summary:
For the nine months ended 30 September 2005, Amgen, Inc.'s revenues rose 20% to $9.16B. Net income rose 70% to $2.85B. Revenues reflect higher demand for Aranesp(R), ENBREL(R) and Neulasta(R). Net income benefited from decreased selling, general & administrative expenses as a percentage of revenues and the absence of write-off of acquired inprocess research & development expenses. The Company is engaged in manufacturing of human therapeutics.

Amgen Inc Business Summary:
Amgen Inc. (Amgen) is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology. It operates in one business segment: human therapeutics. Amgen markets human therapeutic products in the areas of nephrology, supportive cancer care and inflammatory disease. Its principal products include EPOGEN (Epoetin alfa), Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and ENBREL (etanercept), which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. Amgen markets its products to healthcare providers, including clinics, hospitals and pharmacies. The Company operates in the United States, Europe, Canada and Australia. On August 13, 2004, Amgen acquired Tularik Inc. (Tularik). Tularik was a company engaged in drug discovery related to cell signaling and the control of gene expression.